# C_2016125EN.01000701.xml

| 8.4.2016 | EN | Official Journal of the European Union | C 125/7 |
| --- | --- | --- | --- |

8.4.2016

EN

Official Journal of the European Union

C 125/7

---

Prior notification of a concentration

(Case M.7951 Shire/Baxalta)

Candidate case for simplified procedure

(Text with EEA relevance)

(2016/C 125/06)

| 1. | On 1 April 2016, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which Shire plc (Jersey) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of Baxalta Inc. (USA) by way of purchase of shares. |
| --- | --- |

1.

On 1 April 2016, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which Shire plc (Jersey) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of Baxalta Inc. (USA) by way of purchase of shares.

1

| 2. | The business activities of the undertakings concerned are:
  —   Shire plc: a Jersey-registered, Irish-headquartered global specialty biopharmaceutical company. Its pharmaceuticals business is divided into four principal business segments: (1) Neuroscience; (2) Gastrointestinal and Internal Medicine; (3) Ophthalmics; and (4) Rare Diseases;
  —   Baxalta Inc.: a global pharmaceutical company incorporated in Delaware. It specialises in rare diseases and advancing innovative therapies in haematology, immunology and oncology. In particular, Baxalta offers treatments for haemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock. |
| --- | --- |

2.

The business activities of the undertakings concerned are:

—   Shire plc: a Jersey-registered, Irish-headquartered global specialty biopharmaceutical company. Its pharmaceuticals business is divided into four principal business segments: (1) Neuroscience; (2) Gastrointestinal and Internal Medicine; (3) Ophthalmics; and (4) Rare Diseases;

Shire plc

—   Baxalta Inc.: a global pharmaceutical company incorporated in Delaware. It specialises in rare diseases and advancing innovative therapies in haematology, immunology and oncology. In particular, Baxalta offers treatments for haemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock.

Baxalta Inc.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in this Notice. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in this Notice.

2

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number M.7951 Shire/Baxalta, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number M.7951 Shire/Baxalta, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

(2)  OJ C 366, 14.12.2013, p. 5.

2

---